A recent study from the STS/ACC TVT Registry reveals significant variation in how physicians manage antithrombotic medications following valve-in-valve TAVR procedures. Researchers analyzed data from over 18,000 patients between 2015 and 2024 to understand current treatment patterns. The data shows that while dual antiplatelet therapy was common early in the study period, single antiplatelet therapy has become the most frequent strategy by 2024.
Despite the wide range of approaches used by different operators and medical centers, the study found no meaningful difference in patient outcomes. Researchers looked at key metrics such as all-cause mortality, stroke, and bleeding at the one-year mark. The analysis indicates that no single medication regimen demonstrated a clear clinical advantage over the others during this timeframe.
Medical experts suggest that these findings highlight the need for more structured evidence to guide patient care in this specific procedure. While current practice remains inconsistent, the study authors emphasize the importance of local consensus and keeping pace with emerging data. Future clinical trials could provide the definitive answers needed to standardize these treatment protocols.